对现实数据和现实证据对监管决策的两个评估进行比较
Lily Yuan1,2, Motiur Rahman1, John Concato1
1Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
监管机构对现实世界数据 (RWD) 和现实世界证据 (RWE) 的定义有所不同. 协调这些定义对于使用RWE的一致的药物批准决定至关重要.
科学领域:
- 药监和药物开发 药物监督和药物开发
- 监管科学 监管科学
- 健康数据分析数据分析
背景情况:
- 现实世界数据 (RWD) 和现实世界证据 (RWE) 对药物批准的监管决策日益至关重要.
- 监管机构和利益相关者如何定义RWD和RWE存在差异,影响其应用.
- 这种变化可能导致药物的疗效和安全性评估不一致.
结论:
- 对RWD和RWE缺乏一致的定义,阻碍了它们在监管决策中的最佳使用.
- 监管机构和利益相关者之间需要进一步合作,以建立明确和协调的标准.
- 标准化RWE定义将提高药物批准过程的可靠性和效率.
更多相关视频
05:47Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Analysis of Population Pharmacokinetic Data
Hazard Ratio
For example, in a clinical trial...
